Engineering the future of regenerative medicine
From design to precision manufacturing, we partner with you to transform advanced biomaterials into life-changing regenerative therapies.
Engineering the future of regenerative medicine
From design to precision manufacturing, we partner with you to transform advanced biomaterials into life-changing regenerative therapies.
Regenity Biosciences Announces New Allendale Campus, Fueled by Record Growth…
14th April 2026 Regenity Biosciences today announced the signing of a lease on a new facility in Allendale, NJ. The…
Regenity Biosciences Strengthens Executive Leadership Team with Two Strategic Appointments,…
14th April 2026 Company promotes Peggy Hansen to Chief Innovation & Strategy Officer and welcomes Aaron Kendrick as Senior Vice…
Regenity Biosciences receives strategic investment from Cinven, adding new partner…
12th February 2026 Transaction will establish partnership between Regenity, Cinven, and legacy investor Linden Capital Partners to support the Company’s…
Regenity Biosciences to Exhibit at MD&M West 2026
Powering next-generation regenerative medical devices with material expertise, regulatory know-how and disciplined manufacturing execution Paramus, NJ — January 21, 2026 — Regenity Biosciences…
Regenity Demonstrates Next-Generation Regenerative Technologies at MEDICA 2025
At MEDICA 2025, Regenity will showcase how its global CDM business model supports the design, development, and scalability of regenerative…
Regenity Redefines Medical Device Innovation Via Advanced Contract Development and…
Regenity Biosciences has been recognized as a winner of the 2025 R&D 100 Awards for its RejuvaKnee™ meniscal repair innovation.
Regenity Expands Global Footprint with NMPA Approval in China
Milestone Marks Another Dental Product Approval in China’s Fast-Growing Regenerative Sector
Regenity Biosciences Completes First Surgery with RejuvaKnee™, Pioneering Meniscal Repair…
Regenity Biosciences, a global leader in regenerative medicine and Linden Capital Partners portfolio company, today announced the successful completion of…
Regenity Biosciences Receives 510(k) Clearance for RejuvaKnee™, a Groundbreaking Regenerative…
PARAMUS, N.J., Oct. 8, 2024 /PRNewswire/ — Regenity Biosciences, a global leader in regenerative medicine and Linden Capital Partners portfolio…
Regenity Biosciences Receives Regulatory Approval for Collagen Dental Membrane in…
Multicenter Clinical Study Demonstrates Benefits of Regenity’s Novel Crosslinked Collagen Membrane Compared to Geistlich Bio-Gide® Collagen Membrane and Enables Launch…
About Regenity
Powering regenerative science innovation worldwide
Founded in 1997, Regenity is an industry leader in soft and hard tissue regeneration, from private-label products to customized product development partnerships.
Our proprietary bioresorbable technology platforms, proven processes, and ability to leverage a library of design assets enable rapid product iterations and approvals, so we can accelerate your path to market.
Our deep expertise in collagen and synthetic polymer chemistry allows us to engineer scaffolds that serve as a bridge for the body’s natural healing process. We don’t just provide an implant; we provide the structural framework necessary to turn immediate patient needs into permanent, functional tissue restoration.
Video Spotlight
Behind the Innovation: GT Medical Technologies on Partnering with Regenity Biosciences.
Hear from GT Medical Technologies Chief Operating Officer on how Regenity Biosciences’ partnership is helping bring GammaTile – a breakthrough in brain tumor treatment – to the patients who need it most.
Therapeutic Areas
Advancing bioresorbable device innovation across the therapeutic spectrum
Regenity’s unparalleled pipeline of innovation includes more than 30+ million medical devices sold, serving urgent patient needs across a broad range of therapeutic areas and clinical applications.
Therapeutic Areas
Advancing bioresorbable device innovation across the therapeutic spectrum
Regenity’s unparalleled pipeline of innovation includes more than 30+ million medical devices sold, serving urgent patient needs across a broad range of therapeutic areas and clinical applications.
Therapeutic Areas
Advancing bioresorbable device innovation across the therapeutic spectrum
Regenity’s unparalleled pipeline of innovation includes more than 30+ million medical devices sold, serving urgent patient needs across a broad range of therapeutic areas and clinical applications.
Customer Testimonials
Trusted by innovators to navigate the path to market
We’ve worked with partners across the globe—from startups to the world’s leading healthcare companies—to develop life-changing regenerative solutions for the millions of people who need them.
“Regenity did a very good job of investing in their own business during our time of development. Their operative capacity was never in the way of our technology, even though it had an exponential growth curve.”
“I would tell any colleague that was looking at partnering that the breadth of experience and the patent portfolio is a very important and valuable part of what Regenity brings to the table. Their pace of development for creating a unique product is unmatched.”
“I can say unequivocally, all of our interactions with Regenity have proven to meet our requirements and attributes for a professional and seasoned partner with deep expertise. Regenity, having “been there, done that”, is a huge plus for us, or anyone looking for a CDMO in regenerative medicine.”
“The amount of work Regenity put in to help support our FDA submission was a ten out of ten. Regenity had a predicate technology that enabled us to get 510(k) approval very quickly.”
Careers
Join our team
Learn about working at Regenity and how you can make a material difference in the lives of patients every day.
Let’s Connect
Looking for a reliable partner to fill your product portfolio gap, co-create your next great innovation or manufacture your products?